@article{martinez-laperche_ezh2_2022,
	title = {{EZH2} mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment},
	volume = {22},
	issn = {1471-2407},
	shorttitle = {{EZH2} mutations at diagnosis in follicular lymphoma},
	url = {https://doi.org/10.1186/s12885-022-10070-z},
	doi = {10.1186/s12885-022-10070-z},
	abstract = {EZH2 is mutated in nearly 25\% of follicular lymphoma (FL) cases. Little is known about how EZH2 affects patients’ response to therapy. In this context, the aim of this study was to retrospectively analyze the frequency of mutations in EZH2 at diagnosis in tissue and ctDNA in patients with FL and to assess the patients’ outcomes after receiving immunochemotherapy, depending on the EZH2 mutation status. Among the 154 patients included in the study, 27\% had mutated EZH2 (46\% with high-grade and 26\% with low-grade FL). Of the mutated tissue samples, the mutation in ctDNA was identified in 44\% of cases. EZH2 mutation in ctDNA was not identified in any patient unmutated in the tissue.},
	number = {1},
	urldate = {2022-10-18},
	journal = {BMC Cancer},
	author = {Martínez-Laperche, C. and Sanz-Villanueva, L. and Díaz Crespo, F. J. and Muñiz, P. and Martín Rojas, R. and Carbonell, D. and Chicano, M. and Suárez-González, J. and Menárguez, J. and Kwon, M. and Diez Martín, J. L. and Buño, I. and Bastos Oreiro, M.},
	month = sep,
	year = {2022},
	keywords = {EZH2, Follicular lymphoma, Lymphoma solution, R-Bendamustine, R-CHOP},
	pages = {982},
}

{"_id":"sYdrZ2pBCydzFiSCH","bibbaseid":"martnezlaperche-sanzvillanueva-dazcrespo-muiz-martnrojas-carbonell-chicano-surezgonzlez-etal-ezh2mutationsatdiagnosisinfollicularlymphomaapromisingbiomarkertoguidefrontlinetreatment-2022","author_short":["Martínez-Laperche, C.","Sanz-Villanueva, L.","Díaz Crespo, F. J.","Muñiz, P.","Martín Rojas, R.","Carbonell, D.","Chicano, M.","Suárez-González, J.","Menárguez, J.","Kwon, M.","Diez Martín, J. L.","Buño, I.","Bastos Oreiro, M."],"bibdata":{"bibtype":"article","type":"article","title":"EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment","volume":"22","issn":"1471-2407","shorttitle":"EZH2 mutations at diagnosis in follicular lymphoma","url":"https://doi.org/10.1186/s12885-022-10070-z","doi":"10.1186/s12885-022-10070-z","abstract":"EZH2 is mutated in nearly 25% of follicular lymphoma (FL) cases. Little is known about how EZH2 affects patients’ response to therapy. In this context, the aim of this study was to retrospectively analyze the frequency of mutations in EZH2 at diagnosis in tissue and ctDNA in patients with FL and to assess the patients’ outcomes after receiving immunochemotherapy, depending on the EZH2 mutation status. Among the 154 patients included in the study, 27% had mutated EZH2 (46% with high-grade and 26% with low-grade FL). Of the mutated tissue samples, the mutation in ctDNA was identified in 44% of cases. EZH2 mutation in ctDNA was not identified in any patient unmutated in the tissue.","number":"1","urldate":"2022-10-18","journal":"BMC Cancer","author":[{"propositions":[],"lastnames":["Martínez-Laperche"],"firstnames":["C."],"suffixes":[]},{"propositions":[],"lastnames":["Sanz-Villanueva"],"firstnames":["L."],"suffixes":[]},{"propositions":[],"lastnames":["Díaz","Crespo"],"firstnames":["F.","J."],"suffixes":[]},{"propositions":[],"lastnames":["Muñiz"],"firstnames":["P."],"suffixes":[]},{"propositions":[],"lastnames":["Martín","Rojas"],"firstnames":["R."],"suffixes":[]},{"propositions":[],"lastnames":["Carbonell"],"firstnames":["D."],"suffixes":[]},{"propositions":[],"lastnames":["Chicano"],"firstnames":["M."],"suffixes":[]},{"propositions":[],"lastnames":["Suárez-González"],"firstnames":["J."],"suffixes":[]},{"propositions":[],"lastnames":["Menárguez"],"firstnames":["J."],"suffixes":[]},{"propositions":[],"lastnames":["Kwon"],"firstnames":["M."],"suffixes":[]},{"propositions":[],"lastnames":["Diez","Martín"],"firstnames":["J.","L."],"suffixes":[]},{"propositions":[],"lastnames":["Buño"],"firstnames":["I."],"suffixes":[]},{"propositions":[],"lastnames":["Bastos","Oreiro"],"firstnames":["M."],"suffixes":[]}],"month":"September","year":"2022","keywords":"EZH2, Follicular lymphoma, Lymphoma solution, R-Bendamustine, R-CHOP","pages":"982","bibtex":"@article{martinez-laperche_ezh2_2022,\n\ttitle = {{EZH2} mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment},\n\tvolume = {22},\n\tissn = {1471-2407},\n\tshorttitle = {{EZH2} mutations at diagnosis in follicular lymphoma},\n\turl = {https://doi.org/10.1186/s12885-022-10070-z},\n\tdoi = {10.1186/s12885-022-10070-z},\n\tabstract = {EZH2 is mutated in nearly 25\\% of follicular lymphoma (FL) cases. Little is known about how EZH2 affects patients’ response to therapy. In this context, the aim of this study was to retrospectively analyze the frequency of mutations in EZH2 at diagnosis in tissue and ctDNA in patients with FL and to assess the patients’ outcomes after receiving immunochemotherapy, depending on the EZH2 mutation status. Among the 154 patients included in the study, 27\\% had mutated EZH2 (46\\% with high-grade and 26\\% with low-grade FL). Of the mutated tissue samples, the mutation in ctDNA was identified in 44\\% of cases. EZH2 mutation in ctDNA was not identified in any patient unmutated in the tissue.},\n\tnumber = {1},\n\turldate = {2022-10-18},\n\tjournal = {BMC Cancer},\n\tauthor = {Martínez-Laperche, C. and Sanz-Villanueva, L. and Díaz Crespo, F. J. and Muñiz, P. and Martín Rojas, R. and Carbonell, D. and Chicano, M. and Suárez-González, J. and Menárguez, J. and Kwon, M. and Diez Martín, J. L. and Buño, I. and Bastos Oreiro, M.},\n\tmonth = sep,\n\tyear = {2022},\n\tkeywords = {EZH2, Follicular lymphoma, Lymphoma solution, R-Bendamustine, R-CHOP},\n\tpages = {982},\n}\n\n\n\n\n\n\n\n\n\n\n\n","author_short":["Martínez-Laperche, C.","Sanz-Villanueva, L.","Díaz Crespo, F. J.","Muñiz, P.","Martín Rojas, R.","Carbonell, D.","Chicano, M.","Suárez-González, J.","Menárguez, J.","Kwon, M.","Diez Martín, J. L.","Buño, I.","Bastos Oreiro, M."],"key":"martinez-laperche_ezh2_2022","id":"martinez-laperche_ezh2_2022","bibbaseid":"martnezlaperche-sanzvillanueva-dazcrespo-muiz-martnrojas-carbonell-chicano-surezgonzlez-etal-ezh2mutationsatdiagnosisinfollicularlymphomaapromisingbiomarkertoguidefrontlinetreatment-2022","role":"author","urls":{"Paper":"https://doi.org/10.1186/s12885-022-10070-z"},"keyword":["EZH2","Follicular lymphoma","Lymphoma solution","R-Bendamustine","R-CHOP"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://bibbase.org/zotero/SOPHiAGENETICS","dataSources":["Pcpsxmwz8uxXtL843"],"keywords":["ezh2","follicular lymphoma","lymphoma solution","r-bendamustine","r-chop"],"search_terms":["ezh2","mutations","diagnosis","follicular","lymphoma","promising","biomarker","guide","frontline","treatment","martínez-laperche","sanz-villanueva","díaz crespo","muñiz","martín rojas","carbonell","chicano","suárez-gonzález","menárguez","kwon","diez martín","buño","bastos oreiro"],"title":"EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment","year":2022}